This course was last updated on
May 26, 2017
CME credit has expired.


Leonard Calabrese, DO, and Edward Li, PharmD, MPH, BCOP, discuss how to interpret the efficacy and safety data for biosimilar products, and the implications of biosimilars for clinical practice.

Watch the presentation at your own pace.

Download slides to your library.

Read the activity transcript.

Content Areas

  • Pharmacoeconomic impact
  • Burden of evidence
  • Interpreting clinical evidence
  • Practice implications

Target Audience

Rheumatologists, oncologists, dermatologists, gastroenterologists, nephrologists, pharmacists, and other clinicians who currently use or may consider using biosimilars in clinical practice.

This educational activity is supported by an independent medical educational grant from Pfizer.


Leonard Calabrese, DO
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Director, RJ Fasenmyer Center for Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Edward Li, PharmD, MPH, BCOP
Edward Li, PharmD, MPH, BCOP
Associate Professor
Department of Pharmacy Practice
University of New England College of Pharmacy
Portland, Maine
Enter your information to begin.
CME Credit
Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 ACPE Contact Hour
Opens: May 26, 2017
Expires: May 25, 2018
Target Audience: Rheumatologists
Other Health Care Providers